107 related articles for article (PubMed ID: 33084131)
21. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
22. Comparative analysis of programmed cell death ligand 1 assays in renal cell carcinoma.
Lee KS; Choe G; Yun S; Lee K; Moon S; Lee S; Hong SK; Byun SS; Lee SE
Histopathology; 2020 Jul; 77(1):67-78. PubMed ID: 31872892
[TBL] [Abstract][Full Text] [Related]
23. Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?
Diolombi ML; Cheng L; Argani P; Epstein JI
Am J Surg Pathol; 2015 Dec; 39(12):1621-34. PubMed ID: 26426379
[TBL] [Abstract][Full Text] [Related]
24. An extramedullary plasmacytoma in the kidney of a 14-year-old girl: Case report and review of the literature.
Mei YH; Yu JP; Li G
Medicine (Baltimore); 2017 Feb; 96(6):e6092. PubMed ID: 28178171
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of PD-1 and its ligands in renal cell carcinoma.
Erlmeier F; Weichert W; Schrader AJ; Autenrieth M; Hartmann A; Steffens S; Ivanyi P
Med Oncol; 2017 Jun; 34(6):99. PubMed ID: 28432616
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis.
Leite KR; Reis ST; Junior JP; Zerati M; Gomes Dde O; Camara-Lopes LH; Srougi M
Diagn Pathol; 2015 Oct; 10():189. PubMed ID: 26470780
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas.
Yeong J; Zhao Z; Lim JCT; Li H; Thike AA; Koh VCY; Teh BT; Kanesvaran R; Toh CK; Tan PH; Khor LY
J Clin Pathol; 2020 Aug; 73(8):463-469. PubMed ID: 31980560
[TBL] [Abstract][Full Text] [Related]
28. High-grade urothelial carcinoma, plasmacytoid variant, of the renal pelvis with osteoclast-like giant cells and focal rhabdoid features.
Kuroda N; Naroda T; Tamura M; Perez-Montiel D; Michal M; Hes O
Pol J Pathol; 2014 Oct; 65(3):237-40. PubMed ID: 25372422
[TBL] [Abstract][Full Text] [Related]
29. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
30. Low-grade metastases in high-grade clear cell renal cell carcinomas: A clinicopathologic study of 4 cases with an insight into the role of mesenchymal-to-epithelial transition process.
López JI; Mosteiro L; Guarch R; Larrinaga G; Pulido R; Angulo JC
Ann Diagn Pathol; 2016 Feb; 20():13-8. PubMed ID: 26616721
[TBL] [Abstract][Full Text] [Related]
31. Renal plasmacytoma: a case report and summary of reported cases.
Kandel LB; Harrison LH; Woodruff RD; Williams CD; Ahl ET
J Urol; 1984 Dec; 132(6):1167-9. PubMed ID: 6502813
[TBL] [Abstract][Full Text] [Related]
32. Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.
Stoyanoff TR; Rodríguez JP; Todaro JS; Espada JD; Colavita JP; Brandan NC; Torres AM; Aguirre MV
Tumour Biol; 2016 Oct; 37(10):13581-13593. PubMed ID: 27468719
[TBL] [Abstract][Full Text] [Related]
33. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
[TBL] [Abstract][Full Text] [Related]
34. Evaluation and prognostic significance of manganese superoxide dismutase in clear cell renal cell carcinoma.
Zhao Z; Lu J; Qu H; Wang Z; Liu Q; Yang X; Liu S; Ge J; Xu Y; Li N; Yuan Y
Hum Pathol; 2018 Oct; 80():87-93. PubMed ID: 29935195
[TBL] [Abstract][Full Text] [Related]
35. Clear Cell Renal Cell Carcinoma With Borderline Features of Clear Cell Papillary Renal Cell Carcinoma: Combined Morphologic, Immunohistochemical, and Cytogenetic Analysis.
Williamson SR; Gupta NS; Eble JN; Rogers CG; Michalowski S; Zhang S; Wang M; Grignon DJ; Cheng L
Am J Surg Pathol; 2015 Nov; 39(11):1502-10. PubMed ID: 26457355
[TBL] [Abstract][Full Text] [Related]
36. Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
Coppock JD; Volaric AK; Mills AM; Gru AA
Hum Pathol; 2018 Dec; 82():282-288. PubMed ID: 30075155
[TBL] [Abstract][Full Text] [Related]
37. Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
Abbas M; Steffens S; Bellut M; Becker JU; Großhennig A; Eggers H; Wegener G; Kuczyk MA; Kreipe HH; Grünwald V; Schrader AJ; Ivanyi P
Med Oncol; 2016 Jun; 33(6):59. PubMed ID: 27165272
[TBL] [Abstract][Full Text] [Related]
38. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
39. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
[TBL] [Abstract][Full Text] [Related]
40. Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma.
López JI; Pulido R; Lawrie CH; Angulo JC
Ann Diagn Pathol; 2018 Jun; 34():89-93. PubMed ID: 29661736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
